Hannah Koepsell was 11 years old when she was diagnosed with acute lymphoblastic leukemia (ALL), a cancer of the blood and bone marrow. Two years of chemotherapy followed, and in 2024, she rang the ...

Progression-free survival reached 14.3 months with Enhertu versus 8.3 months with chemotherapy plus Keytruda in HER2-mutant ...

For Wyman, that perspective has become part of what comes after his daughter's cancer journey. Emma is now a healthy ...

A reflection on shame, vulnerability and transformation, and how driftwood, the ocean and presence helped reshape one man's ...

Patients with early-stage EGFR-mutated non-small cell lung cancer (NSCLC) who took Tagrisso (osimertinib) for three years ...

In the phase 3 DESTINY-Lung04 trial, patients with HER2-mutant advanced non-small cell lung cancer treated with Enhertu went ...

In this installment of Clinical Trial Corner, Dr. Dina Khalaf, a clinical associate professor in the University of Florida ...

WCLC 2026 brought new lung cancer data on HER2-mutant, PD-L1-positive and EGFR exon 20 insertion-positive non-small cell lung ...

Dr. Dina Khalaf breaks down three clinical trials testing oral and targeted regimens for acute myeloid leukemia and myelodysplastic syndrome.

Dr. Doured Daghistani explains how pediatric oncology is shifting toward reducing long-term side effects as childhood cancer survival rates rise.

Please check back later for more content.

A dedicated movement space can serve as a survivorship anchor, reinforcing identity, agency, and continuity through training ...